648 filings
Page 6 of 33
8-K
myycrh6mgmnfu
3 May 21
Other Events
1:23pm
DEFA14A
wjzhs 0qz
30 Apr 21
Additional proxy soliciting materials
12:50pm
8-K
3xo5h vza935ju7gdb
23 Apr 21
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
4:00pm
8-K
0f2hgz1r6 ld84hp8tu
14 Apr 21
Amendments to Articles of Incorporation or Bylaws
11:07am
8-K
j2aj yj2sp6a
25 Feb 21
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4:04pm
8-K
4ujedsvlwcya8 8ga
3 Feb 21
Regulation FD Disclosure
4:16pm
8-K
wxsqyrp26f0app89t8l
3 Feb 21
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
8:36am
UPLOAD
9mjvsej9 oxi
29 Jan 21
Letter from SEC
12:00am
8-K
wqdqxa9
28 Jan 21
Departure of Directors or Certain Officers
9:54pm
CORRESP
djkpzozs5 x9
27 Jan 21
Correspondence with SEC
12:00am
UPLOAD
mnp l5zv5u1j3ea50
22 Jan 21
Letter from SEC
12:00am
CORRESP
090kjzirea aqh
8 Jan 21
Correspondence with SEC
12:00am
UPLOAD
bncv6ne4nyo7 0z
28 Dec 20
Letter from SEC
12:00am
8-K
65418nlsy18dlrjbp6
19 Nov 20
Entry into a Material Definitive Agreement
4:35pm
8-K
qt9uhraeav8uquk mv96
19 Nov 20
Regulation FD Disclosure
11:34am
8-K
n9cm0s77e2jeo sbsf4
12 Nov 20
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
4:03pm